Olmesartan is a medication used to treat high blood pressure [1]. Information regarding its patent status can be found through resources like DrugPatentWatch.com [2].
When does the Olmesartan patent expire?
The specific expiry dates for patents related to olmesartan and its formulations can vary. Companies often hold multiple patents covering different aspects of a drug, including its active ingredient, manufacturing processes, and specific uses [3]. DrugPatentWatch.com tracks these patent expiries, which are crucial for understanding when generic versions of a drug might become available [2].
How do generic olmesartan products become available?
Generic versions of olmesartan can typically enter the market after the expiration of relevant patents, provided they meet regulatory approval standards [3]. The process involves demonstrating bioequivalence to the branded drug. The availability of generics often leads to a decrease in drug pricing [4].
What are the key uses of Olmesartan?
Olmesartan is primarily prescribed to manage hypertension, or high blood pressure [1]. By relaxing blood vessels, it helps to lower blood pressure, reducing the risk of serious cardiovascular events such as heart attack and stroke [5].
What are the potential side effects of Olmesartan?
Common side effects associated with olmesartan include dizziness, fatigue, and upper respiratory tract infections [1]. A more serious, though rare, side effect is olmesartan-medoxomil-induced enteritis, which can cause severe diarrhea and substantial weight loss [6].
Are there alternatives to Olmesartan for high blood pressure?
Yes, there are several classes of medications available to treat high blood pressure. These include other angiotensin II receptor blockers (ARBs) like losartan and valsartan, ACE inhibitors, calcium channel blockers, diuretics, and beta-blockers [5][7]. The choice of medication depends on individual patient factors and medical history [5].
Who manufactures Olmesartan?
The original branded version of olmesartan is marketed as Benicar by Daiichi Sankyo [8]. Following patent expirations, various pharmaceutical companies have developed and marketed generic versions of olmesartan [4].
Why is patent information important for olmesartan?
Patent information is critical for understanding the market exclusivity of olmesartan [3]. It dictates the timeline for generic competition, which directly impacts drug pricing and patient access [2][4]. DrugPatentWatch.com provides a database to track these intellectual property rights [2].
What is the mechanism of action for Olmesartan?
Olmesartan belongs to the ARB class of drugs. It works by blocking the action of angiotensin II, a hormone that constricts blood vessels [1][5]. By inhibiting angiotensin II's effects, olmesartan causes blood vessels to relax and widen, thereby lowering blood pressure [5].
Sources
1. https://www.nhs.uk/medicine-finder/olmesartan/
2. https://drugpatentwatch.com/
3. https://www.fda.gov/drugs/patent-certification-and-clearance/drug-listing-patent-and-marketing-exclusivity-data-orange-book
4. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4940086/
5. https://www.mayoclinic.org/drugs-supplements/olmesartan-oral-route/proper-use/drg-20066390
6. https://www.nejm.org/doi/full/10.1056/NEJMoa0705318
7. https://www.heart.org/en/health-topics/high-blood-pressure/treatment-and-prevention/medications-for-high-blood-pressure
8. https://www.rxlist.com/benicar-drug.htm